A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.
Updated
April 15, 2026 6:01 PM
Close up of a capsule blister pack. PHOTO: UNSPLASH
DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.
The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.
Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.
DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.
Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.
The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.
Keep Reading
Backed by Menlo Ventures, BrainGrid tackles planning gaps as AI makes software building accessible to more founders.
Updated
April 1, 2026 8:37 AM
A phone screen with app icons. PHOTO: UNPSLASH
As artificial intelligence makes it easier to write code, a different problem is starting to surface. Building software is no longer limited by technical skill alone. Increasingly, the challenge lies in deciding what to build, how to structure it, and how to turn an idea into something that actually works.
That shift sits at the centre of BrainGrid, a startup that has raised $1 million in pre-seed funding led by Menlo Ventures, with participation from Next Tier Ventures and Brainstorm Ventures. The company is building what it describes as an AI-powered planning layer for people who want to create software but may not have a technical background.
The timing reflects a broader change in how products are being built. Tools like Claude Code and Cursor have made it possible to generate working code through simple prompts. For many first-time founders, this has lowered the barrier to entry. But writing code is only one part of the process. Turning that code into a reliable product requires structure, sequencing and clarity—areas where many projects begin to fall apart.
In traditional teams, this responsibility sits with product managers who define what needs to be built and in what order. Without that layer, even well-written code can lead to products that feel disjointed or incomplete. Features may not work together, integrations can break and the final product often does not match the original idea.
BrainGrid is designed to address that gap. Instead of focusing on generating code, it helps users map out the structure of a product before development begins. The aim is to give builders a clearer starting point so that the tools they use—whether human or AI—can produce more consistent results.
The company says more than 500 builders have already used it to create software products across areas like fitness, healthcare and productivity. These range from first-time founders experimenting with new ideas to experienced developers working independently. In many cases, the products are already live and generating revenue, suggesting that the demand is not just for experimentation but for building something that can scale.
For investors, the appeal lies in the evolving role of software development. As AI takes on more of the technical work, the value shifts toward defining the problem and structuring the solution. In that sense, planning becomes less of a background task and more of a core capability.
The US$1 million raise is relatively modest, but it points to a larger trend. As more people gain access to AI tools, the number of potential builders expands. What remains limited is the ability to organise ideas into products that work in the real world. If that shift continues, the next wave of software may not be defined by who can code, but by who can plan.